Welcome to the JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, a prestigious open access journal published by FRONTIERS MEDIA SA since 2008, dedicated to advancing research in the fields of pharmacy and pharmaceutical sciences. With its strong rooting in Canada, this journal has established itself within the academic community by consistently delivering high-quality studies and insights, as evidenced by its respectable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science categories for 2023, along with a notable 77th percentile ranking in Pharmaceutical Science on Scopus. Spanning over two decades of publication from 1998 to 2024, the journal focuses on critical research areas including pharmacology, toxicology, and drug development. By providing open access to its articles, the journal ensures that vital scientific information is readily available to researchers, professionals, and students alike, fostering collaboration and innovation within these essential disciplines. We invite you to explore the latest findings and contribute to the ongoing dialogue in pharmaceutical research through this essential platform.

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

DRUG SAFETY is a premier academic journal published by ADIS INT LTD, dedicated to the critical field of pharmacology and toxicology. Since its inception in 1990, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals by providing high-quality, peer-reviewed articles that inform and advance the understanding of drug safety and efficacy. With an impressive impact factor and its current Q1 categorization in Pharmacology across various sub-disciplines, DRUG SAFETY is ranked among the top journals in its field, reflecting its commitment to excellence in scientific research. The journal features a diverse range of studies, reviews, and case reports addressing contemporary issues in drug safety, making it an invaluable tool for academia and industry alike. Although it is not an open-access journal, the content is accessible to subscribers and institutions, ensuring that essential findings in drug safety reach the widest audience possible. As the field evolves, DRUG SAFETY remains at the forefront, driving innovation and improving regulatory practices worldwide.

Therapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.

The Journal of Health and Safety at Work, published by the Iranian Occupational Health Association, is a vital resource for researchers, professionals, and students engaged in the fields of occupational health, safety, and environmental management. With an ISSN of 2251-807X and E-ISSN 2383-2088, this Open Access journal has been dedicated to disseminating knowledge since 2012, ensuring that critical research is accessible to a global audience. The journal’s scope encompasses a diverse range of topics including human factors and ergonomics, safety research, and public health, with a focus on enhancing workplace safety and environmental standards. Although currently positioned in the Q4 category across various disciplines within safety and health research, the journal offers a unique platform for emerging studies and innovative practices, making it a significant contributor to the discourse in these fields. The journal's commitment to open access aligns with the growing trend of transparent scholarship, thus facilitating the sharing of vital insights to improve workplace health and safety outcomes. Researchers aiming to publish groundbreaking studies in this pivotal area will find the Journal of Health and Safety at Work an indispensable avenue for advancing knowledge and fostering professional collaboration.

JOURNAL OF PHARMACY TECHNOLOGY is a premier publication in the field of Pharmaceutical Science, established in 1989 and published by SAGE PUBLICATIONS INC. This journal serves as an essential resource for professionals, researchers, and students dedicated to the advancements in pharmacy technology and the application of innovative solutions in pharmaceutical practices. With an ISSN of 8755-1225 and an E-ISSN of 1549-4810, the journal provides a rigorous peer-reviewed platform for disseminating cutting-edge research and case studies. As of 2023, it is ranked Q3 in the Scopus categories of Pharmacology, Toxicology, and Pharmaceutics, highlighting its relevance in the field. Although it currently does not offer an Open Access option, JOURNAL OF PHARMACY TECHNOLOGY aims to remain a critical avenue for scholarly communication and knowledge dissemination among practitioners in the pharmaceutical sector, ensuring they stay informed of the latest trends and findings that impact their work.

Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.